Alchemia's Cancer Treatment Shows Early Promise in Lung Cancer Trial
Alchemia, Brisbane, Australia (ASX: ACL):Alchemia's lead cancer product from its HyACT® technology, HA-Irinotecan, was featured on Channel Seven News at 6pm yesterday in most regions, and was also featured on Seven's Sunrise program this morning (Wednesday 28th September) at 6.45am. The first two Small Cell Lung Cancer (SCLC) patients who received HA-Irinotecan have responded very rapidly to the first dose, experiencing substantial shrinkage of their tumours after only ten days. Both patients were treated as part of a Phase II clinical study conducted at Monash Cancer Centre.
The Principal Investigator of the trial Dr Vinod Ganju said: "We are excited by these early responses to treatment, mostly because of the speed of the tumour regressions. Typically we would anticipate achieving a measurable response to therapy after one to two months of treatment but, in the case of the patients treated with HA-Irinotecan, we could measure tumour shrinkage in a matter of days."
Alchemia Oncology's Chief Scientific Officer, Professor Tracey Brown described these early responses as "extremely encouraging" whilst emphasizing that the effectiveness of the treatment will need to be confirmed with further patient data. "The rapidity of the responses is consistent with results from preclinical studies of HA-Irinotecan in lung cancer," she added.
The current study is examining the effectiveness of HA-Irinotecan, which utilises Alchemia's patented HyACT® technology to target the anti-cancer drug irinotecan to the tumour. Patients are randomized to receive either HA-Irinotecan or irinotecan. The parameters that are being assessed include safety and measures of effectiveness such as Progression-Free Survival (PFS). In addition, the study will assess the impact of the treatments on circulating tumour cells (the number of cancer cells detected in the blood) and certain cell populations such as cancer stem cells in the tumour.
Alchemia's HyACT platform works by delivering a higher concentration of the drug to the tumour and enhancing the uptake of the drug by cancer cells. It achieves this by targeting the drug to a specific protein, CD44, that is expressed at high levels by the cells in solid cancers such as breast, lung and colorectal. The technology has been shown to enhance the activity of a broad range of drugs across a number of preclinical models of different cancers. An earlier Phase II study in colorectal cancer with HA-Irinotecan showed a statistically significant improvement in progression- free survival compared with irinotecan (20.8 vs 9.6 weeks, p=0.017). Recruitment to a pivotal Phase III study in colorectal cancer is expected to commence in 2011.
Download this document